Everything below concerns metabolic research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Dietary recommendations === The US Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for selenium in 2000. If there is not sufficient information to establish EARs and RDAs, an estimate designated Adequate Intake (AI) is used instead. The current EAR for selenium for people ages 14 and up is 45 μg/day. The RDA is 55 μg/day. RDAs are higher than EARs so as to identify amounts that will cover people with higher-than-average requirements. RDA for pregnancy is 60 μg/day. RDA for lactation is 70 μg/day. For children ages 1–13 years, the RDA increases with age from 20 to 40 μg/day. As for safety, the IOM sets Tolerable upper intake levels (ULs) for vitamins and minerals when evidence is sufficient. In the case of selenium, the UL is 400 μg/day. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs). The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the United States. For women and men ages 15 and older, the AI is set at 70 μg/day. AI for pregnancy is 70 μg/day; for lactation, 85 μg/day. For children ages 1–14 years, the AIs increase with age from 15 to 55 μg/day. These AIs are higher than the U.S. RDAs. The European Food Safety Authority reviewed the same safety question and set its UL at 300 μg/day, which is lower than the U.S. value.
Muscimol, the compound from which gaboxadol was derived, is a naturally occurring constituent of Amanita mushrooms such as Amanita muscaria (fly agaric) and is a potent GABAA receptor agonist similarly. However, muscimol is less selective, more toxic, and far less-researched than gaboxadol. Muscimol is reported to induce sleep in humans in addition to its well-known hallucinogenic effects that occur at sufficiently high doses. The drug shows similar effects on sleep in rodents as gaboxadol. By the mid-2020s, microdosing of muscimol and Amanita mushrooms for claimed therapeutic benefits, the most prominently cited of which is improved sleep, has become increasingly prominent.
=== Pharmacokinetics === Due to poor oral absorption, teicoplanin requires intravenous or intramuscular administration for systemic effect. Intramuscular administration achieves approximately 90% bioavailability. The drug exhibits high protein binding (90-95%) and is primarily eliminated through the kidneys unchanged, with minimal liver metabolism (2-3%) via hydroxylation. Clearance is reduced in patients with kidney impairment and is not significantly removed by hemodialysis. Teicoplanin exhibits a long half-life of 45-70 hours, allowing for once-daily dosing after loading doses. Although teicoplanin is primarily approved for intravenous and intramuscular use, several clinical and pharmacokinetic studies have explored its administration via the subcutaneous route. Subcutaneous teicoplanin has been reported as a feasible alternative in selected patients, particularly in outpatient, frail, or palliative care settings. Available evidence suggests that subcutaneous administration achieves pharmacokinetic and pharmacodynamic exposures comparable to intravenous dosing after appropriate loading, with good local tolerability. However, this route of administration remains off-label.
=== G protein and β-arrestin pathways === KOR activation initiates both G protein-mediated and β-arrestin-dependent signaling pathways. Following agonist binding, activated Gαi subunits inhibit adenylyl cyclase activity, whilst Gβγ dimers activate G protein-coupled inwardly rectifying potassium channels (GIRKs) and inhibit calcium channels. G protein signaling also initiates early-phase phosphorylation of ERK through Gβγ-mediated activation of phosphoinositide 3-kinase (PI3Ks). After G protein activation, G protein-coupled receptor kinases (GRKs) phosphorylate the receptor, which promotes recruitment of β-arrestins. Their recruitment mediates receptor desensitization, internalization, and downregulation, whilst also initiating distinct signaling cascades independent of G protein activation. β-arrestin2 is the dominant isoform mediating KOR desensitization, β-arrestin1 recruitment to KOR is possible but appears weaker and less functionally significant. β-Arrestin2-mediated signaling includes late-phase ERK phosphorylation and activation of p38 MAPK and c-Jun N-terminal kinase (JNK). Repeated stress produces dynorphin-dependent activation of both KOR and p38 MAPK within GABAergic neurons localized to the nucleus accumbens, prefrontal cortex, and hippocampus. This p38 activation is dependent upon G protein-coupled receptor kinase 3 (GRK3) and β-arrestin2 recruitment and occurs through Ser369 phosphorylation of KOR itself.
Sources: en.wikipedia.org
This philosophy extended to the use of the little girls as drones (now Little Sisters), particularly the question whether the player should try to save the girls or harvest the ADAM for their benefit. 2K Games expressed concern about the initial mechanic of the Little Sisters, where the player would actively prey on the Little Sister, which would have alerted a Big Daddy and set up the fight with the player. This approach did not sit well with Levine, and 2K Games asserted that they would not ship a game "where the player gets punished for doing the right thing". They altered this approach where the Little Sisters would be invulnerable until the player had dealt with their Big Daddy, though LeBreton considered this "a massive kludge" into the game's fiction. The idea of creating the Little Sisters and presenting the player with this choice became a critical part of the game's appeal to the broader gaming market, although it was met with criticism from some outlets. Levine desired only to have one ending to the game, something that would have left the fate of the characters "much more ambiguous", but publisher pressure directed them to craft multiple endings depending on the choice of harvesting Little Sisters. Levine also noted that "it was never my intention to do two endings for the game. It sort of came very late and it was something that was requested by somebody up the food chain from me." Other elements came into the story design. Levine had an interest in "stem cell research and the moral issues that go around [it]".
== Debate over treatment approaches == Despite some evidence showing that all the major therapeutic orientations are about of equal effectiveness, there remains much debate about the efficacy of various forms of treatment in use in clinical psychology.
An oligopeptide (oligo-, "a few"), is a peptide consisting of two to twenty amino acids, including dipeptides, tripeptides, tetrapeptides, and other polypeptides. Some of the major classes of naturally occurring oligopeptides include aeruginosins, cyanopeptolins, microcystins, microviridins, microginins, anabaenopeptins, and cyclamides. Microcystins are best studied because of their potential toxicity impact in drinking water. A review of some oligopeptides found that the largest class are the cyanopeptolins (40.1%), followed by microcystins (13.4%).
Sources: en.wikipedia.org
the alternation of late wood and early wood increments within the annual ring; the influence of wood rays on the radial direction; the features of the cell wall structure such as microfibril angle modifications and pits; the chemical composition of the middle lamella. Wood drying may be described as the art of ensuring that gross dimensional changes through shrinkage are confined to the drying process. Ideally, wood is dried to that equilibrium moisture content as will later (in service) be attained by the wood. Thus, further dimensional change will be kept to a minimum. It is probably impossible to completely eliminate dimensional change in wood, but elimination of change in size may be approximated by chemical modification. For example, wood can be treated with chemicals to replace the hydroxyl groups with other hydrophobic functional groups of modifying agents. Among all the existing processes, wood modification with acetic anhydride has been noted for the high anti-shrink or anti-swell efficiency (ASE) attainable without damage to wood. However, acetylation of wood has been slow to be commercialised due to the cost, corrosion and the entrapment of the acetic acid in wood. There is an extensive volume of literature relating to the chemical modification of wood. Drying timber is one method of adding value to sawn products from the primary wood processing industries.
==== 1952–53 ==== When he joined the Cardinals, broadcaster Harry Caray started calling him "Vinegar Bend," and the nickname stuck. He was hailed as "the left-handed Dizzy Dean" by sportswriter Red Smith, which Mizell called "a perty heavy load for a boy to tote." Added to St. Louis's starting rotation for the 1952 campaign, Mizell made his major league debut on April 22 against the Cincinnati Reds. He gave up two runs in the first inning, then held the Reds scoreless for the rest of the game, though he took the loss in a 2–1 defeat. Two starts later, on May 2, he limited the Philadelphia Phillies to four hits and two runs in a complete game, winning in the ninth when Peanuts Lowrey broke a 2–2 tie with an RBI-single. After that win, he lost three games in a row, then received four consecutive no decisions. He ended the winless streak on June 21, when he struck out 11 in his first major league shutout against the Boston Braves. That started a streak of six decisions won in a row, during which time Mizell posted a 3.05 ERA. He would not lose again until August 27. On September 5, he threw his second shutout of the year, tying his season high with 11 strikeouts in a 4–0 victory over the Pittsburgh Pirates. Mizell finished his rookie season with a 10–8 record and a 3.65 ERA in 30 starts. He led the National League (NL) in strikeouts per 9 innings pitched with a 6.9 mark, and his 146 strikeouts ranked fourth in the league (behind Warren Spahn's 183, Bob Rush's 157, and Robin Roberts's 148). However, he also led the league in walks (103, tied with Herm Wehmeier).
=== Background and education === Galloway was born in Dundee, Scotland on 16 August 1954, to George Galloway Sr., a Scottish trade unionist, and Sheila O'Reilly, a Scot of Irish descent. Initially raised in Lochee, Dundee, he has described himself as "born in an attic in a slum tenement in the Irish quarter of Dundee, which is known as Tipperary". His father began as an electrician, before studying a degree to become an electromechanical engineer at NCR. After being made redundant, he retrained as a teacher. His mother was a cleaner, and then a factory worker. According to Galloway, his father was patriotic, while his mother had Irish nationalist sympathies, and was critical of perceived British pretensions in the world. He took his mother's side in arguments, and has been a long-time supporter of Sinn Féin and Irish reunification. David Morley, his biographer, has written that people who knew both father and son have said that they had Marxist opinions common in the local Labour Party movement of the time. Galloway grew up in Charleston, Dundee, and attended Charleston Primary and then Harris Academy, in the city's West End, an academically selective and non-denominational state school, which became comprehensive in 1973. Galloway played for the school football team as well as for West End United U12s, Lochee Boys Club U16s and St Columba's U18s.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.